GENERAL ASPECTS OF MENOPAUSAL HORMONAL THERAPY (M.H.T.)

KONSTANTINE KHARABADZE; DAVID KOBESHAVIDZE; ZAZA BOKHUA

doi:10.52340/jecm.2023.03.01

GENERAL ASPECTS OF MENOPAUSAL HORMONAL THERAPY (M.H.T.)

Авторы

KONSTANTINE KHARABADZE
DAVID KOBESHAVIDZE
ZAZA BOKHUA

DOI:

https://doi.org/10.52340/jecm.2023.03.01

Ключевые слова:

Menopausal hormonal therapy (M.H.T.), Drospirenone, Endometrium, menopause

Аннотация

Different aspects of M.H.T. are discussed. This type of replacement therapy intended for treatment of menopausal complains as well as for prevention of cardiovascular disorders and osteoporosis. Prescription of M.H.T. based on accurate assessment of benefits/risks ratio. Low, effective dose of hormones (Э – 0,5mg/drospirenone – 0,25mg) is recommended in continuous regime, for peroral administration.

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

Adamyan L.V., Melnikova N.S., et al. Pathology of the endometrium in the elderly and senile age (screening study). Archive of Pathology. 2013; 75(6): 32-8. (In Russian).

Aksel E.M. Morbidity and mortality from malignant neoplasms of the female reproductive system in Russia. Oncogynecologia. 2015; (1): 4-13. (In Russian).

Baber R.J., Panay N., et al. JMS Writing Group. 2016 JMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.

Canonico M., Oger E., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5.

Canonico M., Faurnier A., et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5.

Caprio M., Zennaro M.C., et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric. 2008; 11(3): 258-64.

Carugno J. Clinical management of vaginal bleeding in postmenopausal women 2020. Climacteric. 2020; Apr 1:1-7.

Chlebowski R.T., Anderson G.L., et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304(15): 1684-92.

Chlebowski R.T., Luo J., et al. Weight loss and breast cancer incidence in postmenopausal women. Cancer. 2019; 125(2): 205-12.

Colombo N., Preti E., et al. ESMO Guidelines Working Group. Endometrial cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(6):33-8.

Dinger J. Bardenheuer K., et al. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016; 19(4): 349-56.

Gambacciani M., Cagnacci A., et al. Hormone replacement therapy and prevention of chronic conditions. Climacteric. 2019; 22(3): 303-6.

Gass M.L., Maki P.M., et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015; 22(7): 685-6.

Gerlinger C., Gude K., et al. Recommendation for the collection and analysis of endometrial biopsies for hormone therapies. Climacteric. 2012; 15: 52-8.

Gerlinger C., Gude K., et al. 0,5 vs. 1,0mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric. 2015; 18(4): 512-7.

Grigoryan O.R. Efficacy and safety of the use of ultra-low doses of drospirenone and 17β - estradiol in postmenopausal women. Meta-analysis. Medical Advice. 2018; (7): 126-32.

Hodis H.N., Sarrel P.M. Menopausal hormone therapy and breast cancer: What is the evidence from randomized trials? Climacteric. 2018; 21(6): 521-8.

Hunter M.S. The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of their emotional and physical health. Psychol. Health. 1992; 7: 45-54.

Joseph J.J., Echouffo Tcheugui J.B., et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA. J. Am. Heart Assoc. 2019; 7(17): e009890.

Menopauzal’naya gormonoterapya I sokhranenie zdorov’ya zhenshchin v zrelom vozraste. Klinicheskie rekomendatsii (protocol lecheniya). Pis’mo Ministerstva zdorovookhraneniya Rossiiskoi Feretatsii ot 2 Oktober 2015. N15-4/10/2-5804. (In Russian).

Renoux C., Dell’Aniello S., et al. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86.

Rossouw J.E., Anderson G.I. et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33.

Rubin R. Postmenopausal women with a „normal“ BMI might be overweight or even obese. JAMA. 2018; 319(12): 1185-7.

Schindler A.E., Campagnoli C., et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80.

Slopien R., Wender-Ozegowska E., et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6-10.

Straczek C., Oger E., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22): 3495-500.

Sturdee D.W., Pines A.: International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14: 302-20.

Trabert B., Wentzensen N., et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int. J. Cancer. 2013; 132(2): 417-26.

Vinogradova Y., Coupland C., et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q-Research and CPRD databases. BMJ. 2019; 364: K4810.

Wright A.K., Kontopanteliz E., et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. Circulation. 2019; 139(24): 2742-53.